PAQ Therapeutics, Inc.
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).
Inclusion Criteria: * Men or women less than or equal to (\>=) 18 years of age * Histologically or cytologically confirmed advanced or metastatic solid malignancy * Participant has a pathologically documented, locally advanced or metastatic malignancy with any KRAS mutation or wild-type (WT) KRAS amplification identified through molecular testing using a Clinical Laboratory Improvement Amendments (CLIA) certified, validated institutional or commercial test * Participant must have received at least 1 and no more than 4 prior systemic therapies or be intolerant or ineligible for available thera…
Intravenous infusion.
Intravenous infusion.